Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

NOT YET RECRUITING

NCT07228195

PHASE4

SGLT2i Therapy in Islet Transplantation (SIT)

Sponsor: University of Minnesota

View on ClinicalTrials.gov

Summary

This pilot clinical trial is designed to gather preliminary data on the efficacy and safety of empagliflozin, a diabetes drug in the sodium-glucose cotransporter 2 inhibitor (SGLT2i) class, in islet autotransplant recipients who have partial islet function.

Key Details

Gender

All

Age Range

18 Years - 70 Years

Study Type

INTERVENTIONAL

Enrollment

Start Date

2026-05-15

Completion Date

2028-12-01

Last Updated

2026-03-19

Healthy Volunteers

Conditions

Partial Islet Function TPIAT Diabetes

Interventions

DRUG

Empagliflozin 25 MG Oral Tablet

Empagliflozin, which is sold under the name of Jardiance, is FDA approved for patients 10 years of age and older to improve glycemic control in type 2 diabetes.

DRUG

Empagliflozin 10 MG Oral Tablet [Jardiance]

Empagliflozin, which is sold under the name of Jardiance, is FDA approved for patients 10 years of age and older to improve glycemic control in type 2 diabetes.

Inclusion Criteria: * Age 18-70 years old; * \>1 year after TPIAT date at enrollment; * Partial islet function defined as stimulated C-peptide ≥0.6 ng/mL at screening/baseline visit, AND either (1) on insulin at ≤0.25 unit/kg/day OR (2) not on insulin but HbA1c \>6.5%; * Stable diabetes management defined by stable on pump or multiple daily injections (MDI) for at least 8 weeks and \<25% change in insulin dosing over prior 8 weeks. * Willing to manage diabetes medication management/dose adjustments for the duration of the study with study team MD * Willing to wear continuous glucose monitor for diabetes management (currently standard of care for TPIAT diabetes) * Willing to record insulin doses for 14 day intervals x 3 study visits. * Willing and able to come to the UMN Clinical Research Unit for 3 study visits, approximately 3 months apart * No prescribed medications other than insulin to treat diabetes in the past 4 weeks. Exclusion Criteria: * HbA1c \>9%; on any non-insulin antihyperglycemic medication; * History of diabetic ketoacidosis (DKA) in the past 1 year; * Unable to drink Boost HP due to true milk protein allergy; * Underweight (BMI \<18.5 kg/m2) \[contraindicated by possible weight loss with SGLT2 inhibitors\]; * Renal failure defined by glomerular filtration rate \<30 mL/min/m2; * Recurrent dehydration necessitating ED/hospital visits; one time/ rare hospital visits due to intercurrent illness are not exclusionary but repeated dehydration from a chronic condition will be exclusionary. * Expected to need systemic corticosteroids at \>25 mg/day hydrocortisone equivalent over the 6-month study interval; * Known allergy to empagliflozin; * Currently pregnant or plan to become pregnant in the next 6 months (for females), or currently breastfeeding; * Unwillingness to consent or return for study visits; * Non-English speaking. * Any other medical contraindication to treatment or study participation in the opinion of the investigator that would impact either patient's safety or their ability to complete the study.

Locations (1)

University of Minnesota

Minneapolis, Minnesota, United States